EGFR and non-small cell lung carcinoma: The SINDAS trial is a phase III trial of newly diagnosed, oligometastatic EGFR-mutated NSCLC (≤5 oligometastases and no intracranial disease) randomized to receive TKI therapy alone or upfront SBRT to all sites of disease in addition to TKI therapy.